IGHV4-28: A Potential Drug Target for T-Cell Receptor Signaling and Inflammation

Target Name: IGHV4-28

NCBI ID: G28400

IGHV4-28

Other Name(s): IGHV428 | immunoglobulin heavy variable 4-28 | Immunoglobulin heavy variable 4-28 | VH

IGHV4-28: A Potential Drug Target for T-Cell Receptor Signaling and Inflammation

IGHV4-28 (IGHV428) is a protein that is expressed in most tissues of the human body. It is a member of the interleukin-4 (IL4) family and is involved in the regulation of immune responses, inflammation, and cell survival. IGHV4-28 has been identified as a potential drug target (or biomarker) due to its unique structure and the involvement in several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

The IGHV4-28 protein is a 28-kDa glycoprotein that is expressed in most tissues of the human body, including the brain, spleen, heart, lung, and kidney. It is a single-pass transmembrane protein that consists of an N-terminus, a catalytic domain, and a C-terminus. The N-terminus of IGHV4-28 contains a unique farnesylated cysteine residue, which is important for its stability and localization in the membrane.

IGHV4-28 is involved in the regulation of immune responses, inflammation, and cell survival. It is a key signaling molecule in the T-cell receptor (TCR) signaling pathway, which is involved in the regulation of immune responses to intracellular antigens. IGHV4-28 has been shown to play a role in the regulation of T-cell activation, proliferation, and differentiation.

In addition to its role in TCR signaling, IGHV4-28 is also involved in the regulation of inflammation and cellular stress. It has been shown to play a role in the regulation of inflammation by suppressing the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. IGHV4-28 has also been shown to play a role in the regulation of cellular stress, including the regulation of cell death and the modulation of cell survival.

IGHV4-28 has been identified as a potential drug target due to its unique structure and the involvement in several diseases. It is a good candidate for small molecule inhibitors, such as drugs that can modulate the activity of IGHV4-28, such as those that target its farnesylated cysteine residue or its role in TCR signaling. In addition to small molecules, IGHV4-28 may also be a good candidate for monoclonal antibodies (MCAs), which are a type of immunotherapy that can target specific proteins and have the potential to treat a variety of diseases.

In conclusion, IGHV4-28 is a protein that is expressed in most tissues of the human body and is involved in the regulation of immune responses, inflammation, and cell survival. Its unique structure and involvement in several diseases make it a potential drug target (or biomarker) that can be targeted by small molecules or MCAs. Further research is needed to fully understand the role of IGHV4-28 in disease and to develop effective treatments.

Protein Name: Immunoglobulin Heavy Variable 4-28

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV4-28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV4-28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets